GSA Capital Partners’s Castle Biosciences CSTL Stock Holding History

GSA Capital Partners’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$300K	Buy	+12,236	New	+$401K	0.02%	1250
2025 Q2	–	Sell	-67,143	Closed	-$1.34M	–	1801
2025 Q1	$1.34M	Sell	67,143 -3,658	-5%	-$90.6K	0.12%	210
2024 Q4	$1.89M	Buy	70,801 +18,974	+37%	+$578K	0.14%	97
2024 Q3	$1.48M	Buy	+51,827	New	+$1.32M	0.11%	226
2024 Q2	–	Sell	-52,448	Closed	-$1.16M	–	1687
2024 Q1	$1.16M	Buy	52,448 +4,352	+9%	+$94.7K	0.09%	349
2023 Q4	$1.04M	Sell	48,096 -4,099	-8%	-$72.1K	0.09%	372
2023 Q3	$882K	Buy	52,195 +11,280	+28%	+$197K	0.08%	470
2023 Q2	$561K	Buy	40,915 +8,626	+27%	+$175K	0.06%	671
2023 Q1	$734K	Buy	32,289 +5,393	+20%	+$132K	0.07%	485
2022 Q4	$633K	Sell	26,896 -38,353	-59%	-$889K	0.08%	452
2022 Q3	$1.7M	Buy	+65,249	New	+$1.83M	0.23%	34

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's CSTL Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Castle Biosciences (CSTL) in Q1 2026: 12,236 shares worth $300K. The stake represents 0.02% of the portfolio and ranks #1250 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in CSTL as recently as Q1 2025.

GSA Capital Partners first reported a position in CSTL in Q3 2022 and has held it in 11 quarters since. The position peaked at $1.89M in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

GSA Capital Partners held 12,236 shares of Castle Biosciences worth $300K as of Q1 2026.
Castle Biosciences was a new GSA Capital Partners position in Q1 2026.
Castle Biosciences made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1250 holding.
GSA Capital Partners first reported a position in Castle Biosciences in Q3 2022 and has held it in 11 quarters since.
GSA Capital Partners's Castle Biosciences position peaked at $1.89M in Q4 2024.
186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.